Chinese Language Podcast: ESMO China Data, Annual CDE Report, Shanghai Biopharma Week

Chinese oncology developers including BeiGene, Ltd., Jiangsu Hengrui Medicine Co., Ltd. and Shanghai Junshi Biosciences Co., Ltd. all released new clinical data during the recent European Society for Medical Oncology (ESMO) meeting.

What were some of the highlights and notable results, in particular against emerging targets such as KRAS G12D? (Also see "ESMO 23: Kelun/Merck, Hansoh ADCs Impress With Early Data In Breast Cancer" - Scrip, 20 Oct, 2023.)

In other recent hot China biopharma topics covered in this Chinese-language podcast, China's Center for Drug Evaluation released its annual report for 2022, which highlighted several key trends in clinical trial and new drug approval activity in the country. (Also see "China New Drug Trials Momentum Tapering, Regulatory Changes Looming" - Pink Sheet, 16 Oct, 2023.)

Meanwhile, the Shanghai municipal government organized its major international biopharma week for the third year in a row from 16-20 October. Shanghai-based Scrip senior editor Dexter Yan makes some observations on his in-person attendance at the event. 

If you have any suggestions, comments or ideas, please contact the authors at the email addresses above. 

This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.  

在今年的ESMO上，中国生物药企有何亮点？比如在ADC药物的研发上，有哪些早期临床数据读出？除了ADC药物，还有哪些值得关注的临床结果，比如在KRAS G12D，或者三期临床数据读出方面？

中国新药审评中心（CDE）的《2022新药审评报告》中，中国新药临床试验出现哪些趋势？这些趋势对于中国生物新药研发有哪些启示？

最后，今年是上海第三次举办一年一度的国际生物医药产业周活动，和往年相比，有何不同？在政策端，上海市政府为了提振和进一步发展生物医药产业有什么值得关注的举措？

欢迎和我们电邮联系。

下期节目见！